Publications by authors named "R T Chlebowski"
Article Synopsis
- The study explores how social support, social strain, and stressful life events can impact survival rates among women diagnosed with breast cancer, particularly focusing on the role of psychosocial factors in mortality.
- Researchers analyzed data from 9,154 postmenopausal women diagnosed with invasive breast cancer, examining the relationships between various psychosocial factors and different types of mortality over an average follow-up of 8.6 years.
- Results indicated that higher social support was linked to lower all-cause mortality, while high social strain correlated with decreased cardiovascular disease mortality, with differences observed based on race among participants.
Article Synopsis
- A study examined the effects of opioid use in breast cancer survivors after treatment, comparing them with age-matched women without cancer, focusing on health risks.
- The results showed that breast cancer survivors used more opioids and had a higher risk of falls, fractures, lung problems, and cardiovascular events compared to non-users.
- The findings highlight the need for careful monitoring of opioid prescriptions in breast cancer survivors and the importance of exploring alternative pain management strategies.
Background: While the Breast Cancer Risk Assessment Tool (BCRAT) predicts breast cancer incidence, the model's performance, re-purposed to predict breast cancer mortality, is uncertain. Therefore, we examined whether the BCRAT model predicts breast cancer mortality in postmenopausal women in the Women's Health Initiative (WHI).
Methods: BCRAT 5-year breast cancer incidence risk estimates were calculated for 145,408 women (aged 50-79 years) enrolled in the WHI at 40 US clinical centers to examine associations of BCRAT risk groups (< 1%, 1-< 3%, ≥ 3%) with breast cancer mortality using Cox proportional regression modeling in all participants and in those with incident breast cancer.
Purpose: Menopausal hormone therapy's influence on ovarian and endometrial cancers remains unsettled. Therefore, we assessed the long-term influence of conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) and CEE-alone on ovarian and endometrial cancer incidence and mortality in the Women's Health Initiative randomized, placebo-controlled clinical trials.
Materials And Methods: Postmenopausal women, age 50-79 years, were entered on two randomized clinical trials evaluating different menopausal hormone therapy regimens.
JCO We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg, or placebo.
View Article and Find Full Text PDF